2022 Press Releases - 2022-10-21

Cerba And Taliaz to leverage Artificial Intelligence and Genetics Expertise to improve patient care management in depression

Saint Ouen l’Aumône (France) and Tel Aviv (Israel), October 20th, 2022 - Cerba, the foremost specialty clinical pathology reference, and Taliaz, an Israeli digital health company dedicated to improving mental health disorders, announced today a partnership to provide physicians with an AI-driven precision psychiatry solution that predicts treatment effectiveness in depression.

2022 Press Releases - 2022-10-05

Cerba Lancet Africa signs strategic partnership with international Clinical Laboratories in Ethiopia

Johannesburg (South Africa) and Addis-Ababa (Ethiopia), 29th September 2022 - Cerba Lancet Africa, a benchmark in the field of medical diagnosis in Africa, today announced it has signed a strategic partnership with International Clinical Laboratories (ICL) Ethiopia, the leading private clinical pathology laboratory in the country serving more than 3 million patients over the past 17 years.

2022 Press Releases - 2022-07-18

Cerba Lancet Nigeria commits to provide optimal diagnostic in Nigeria

Olayemi Dawodu, the managing director/CEO of , Cerba Lancet Nigeria a leading ultramodern pathology laboratory with branches across multiple states in Nigeria has reiterated the company’s commitment to providing optimal diagnostic services to patients using advanced technology across all laboratories in the country.

2022 Press Releases - 2022-02-14

Clina-Lancet Laboratories Approved for COVID-19 Testing

Clina-Lancet Laboratories has been approved for private testing of COVID-19 to expand the testing capacity of Lagos State.

2022 Press Releases - 2022-02-14

Clina-Lancet Laboratories opens world class facility in Maitama Abuja

2022 Press Releases - 2022-02-14

Cerba Lancet Africa

Clina-Lancet Laboratories, a long standing player in the medical diagnostic sector in Nigeria is pleased to announce that Cerba Lancet Africa based in Paris has acquired a controlling interest in our company.